文献速递免疫规划

Tropis无针注射器用于分次剂量IPV接种:古巴将其整合入常规免疫服务的试点研究

Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba.
PubMed 文献 · Vaccine · 2025-02-22

研究在古巴Camagüey于2019至2020年试点Tropis无针喷射注射器接种分次剂量脊髓灰质炎灭活疫苗(fIPV),评估可接受性、安全性和免疫原性。98%家长和98.5%护士偏好Tropis;Tropis不良事件少于针筒(6%[14/238] vs 13%[20/157],p=0.028);两剂后三个血清型血清阳性率与针筒无显著差异。因注射器相关成本增加,古巴政府未将Tropis纳入常规免疫规划。

要点

  • 98%家长和98.5%护士偏好Tropis无针注射器而非传统针筒。
  • Tropis不良事件发生率6%(14/238)低于针筒13%(20/157),p=0.028。
  • 两剂后三个血清型血清阳性率Tropis与针筒无显著差异,但政府因成本未采纳。

核心结论

  • Tropis在家长和护士中的可接受性看似优于标准针筒,且达到的血清阳性率无显著差异,但古巴政府因主要与注射器相关的成本增加而未将Tropis纳入常规免疫规划。

研究设计与样本

  • 在古巴Camagüey于2019至2020年开展的试点研究,评估Tropis无针喷射注射器接种fIPV的可接受性、安全性和免疫原性并与传统针筒(N/S)比较。
  • 对家长/监护人(n=5260)和护士(n=66)进行满意度调查;分析接种儿童血样中和脊髓灰质炎病毒抗体水平(Camagüey试点Tropis n=231;Ciego de Ávila使用N/S n=138)。

主要发现

  • 98%的家长和98.5%的护士偏好Tropis而非N/S。
  • Tropis不良事件少于N/S(6%[14/238] vs 13%[20/157],p=0.028)。
  • 4月和8月接种两剂后,Tropis与N/S在三个血清型的血清阳性率无显著差异(1型76.2% vs 79%,p=0.53;2型80.5% vs 84.1%,p=0.39;3型51.6% vs 64.5%,p=0.08)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fractional-dose inactivated poliovirus vaccine (fIPV), 1/5th of a standard IPV dose, is used in Cuba's routine immunization (RI) schedule. Tropis, a needle-free jet injector, simplifies intradermal fIPV administration and was piloted in Camagüey, Cuba, from 2019 to 2020. This study assessed Tropis' acceptability, safety, and immunogenicity compared to traditional needle and syringe (N/S) administration. Surveys were administered to parents/guardians (n = 5260) and nurses (n = 66) to evaluate satisfaction. Blood samples from vaccinated children were analyzed for neutralizing poliovirus antibody levels (n = 231 in Camagüey piloting Tropis; 138 in Ciego de Ávila using N/S). Results indicate 98 % of parents and 98.5 % of nurses preferred Tropis over N/S. Adverse events were fewer with Tropis than N/S (6 % [14/238] vs. 13 % [20/157], p = 0.028). After two doses at 4 and 8 months, there was no significant difference between Tropis and N/S administration in seroprevalence levels for all three serotypes (type 1, 76.2 % vs. 79 %, p = 0.53; type 2, 80.5 % vs. 84.1 %, p = 0.39; type 3, 51.6 % vs. 64.5 %, p = 0.08). Although Tropis acceptability seemingly supersedes standard N/S administration (in both parents and nurses) and the achieved seroprevalence did not differ significantly, the government of Cuba did not implement Tropis into its RI program due to increased costs associated primarily with the syringe.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Resik S, Lopez Cavestany R, Tejeda A, et al. Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba. Vaccine. 2025. PMID: 39987881. doi:10.1016/j.vaccine.2025.126903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。